

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A compound from 12 to 50 nucleobases in length targeted to a nucleic acid molecule encoding growth hormone receptor, wherein said compound~~[[;]]~~ comprises an at least an-8 consecutive nucleobase portion of SEQ ID NO: 19; ~~comprises deoxynucleotides in a first region, at least one high affinity modified sugar in each of a second region and a third region, which flank the first region on the 5' end and the 3' end, respectively; and wherein said compound is at least 70%-90% complementary with SEQ ID NO: 4 as measured over the entirety of said compound; and specifically hybridizes with said nucleic acid molecule encoding growth hormone receptor (SEQ ID NO: 4).~~

2. (Canceled)

3. (Currently Amended) A-The compound according to claim 1 which is from 15 to 30 nucleobases in length.

4. (Currently Amended) A-The compound according to claim 1 comprising an oligonucleotide.

5. (Currently Amended) A-The compound according to claim 4 in which the oligonucleotide is an antisense oligonucleotide.

6. (Currently Amended) A-The compound according to claim 4 in which the oligonucleotide is a DNA oligonucleotide.

7. (Currently Amended) A-The compound according to claim 4 in which the oligonucleotide is a RNA oligonucleotide.

8. (Canceled).

9. (Currently Amended) A-The compound according to claim 7 ~~which~~ wherein said compound is a short interfering RNA (siRNA) molecule.

10-12. (Canceled).

13. (Currently Amended) A-The compound according to claim 1 comprising at least 95% complementarity with ~~the nucleic acid molecule encoding growth hormone receptor (SEQ ID NO: 4)~~ as measured over the entirety of said compound.

14.-19. (Canceled)

20. (Currently Amended) ~~A-~~The compound according to claim 1 further comprising at least one modified internucleoside linkage, nucleobase, modified sugar, or combination thereof.

21. (Currently Amended) ~~A-~~The compound according to ~~claim 1~~ claim 20, wherein the ~~high affinity~~-modified sugar is ~~selected from the group consisting of a 2'-O-(2-methoxyethyl), locked nucleic acid or ethylene-bridged nucleic acid~~ and a 4'-(CH₂)_n-O-2' bridge, wherein n is 1 or 2.

22. (Currently Amended) ~~A-~~The compound according to claim 20 comprising at least one phosphorothioate internucleoside linkage.

23. (Currently Amended) ~~A-~~The compound according to claim 20 comprising at least one 5-methylcytosine.

24.-45. (Canceled)

46. (Currently Amended) ~~An-~~The compound of claim 1, wherein said compound is an antisense oligonucleotide comprising a nucleobase sequence of SEQ ID NO: 19 and further comprising a ten deoxynucleotide region flanked on both the 5' and the 3' ends with at least five 2'-O-(2-methoxyethyl) nucleotides, wherein each internucleoside linkage is a phosphorothioate and each cytosine is a 5-methylcytosine.

47. (Currently Amended) A pharmaceutical composition comprising the antisense oligonucleotide of claim 46 and ~~a composition an ingredient~~ selected from the group consisting of a pharmaceutically acceptable carrier, diluent, penetration enhancer, excipient ~~or~~ and combinations thereof.

48-49. (Canceled).

50. (Currently Amended) A compound from ~~12 to 50~~ 15 to 30 nucleobases in length targeted to a nucleic acid molecule encoding growth hormone receptor, wherein said compound comprises at least ~~12-8~~ consecutive nucleobases from SEQ ID NO: 19 and is at least ~~95%-80%~~ complementary with SEQ ID NO: 4 as measured over the entire length of said compound.

51. (Previously Presented) The compound of claim 50 comprising 100% complementarity with SEQ ID NO: 4.

Appl. No. : 10/789,526
Filed : February 26, 2004

52. (Currently Amended) The compound of claim 50 comprising at least one of a modified internucleoside linkage, a ~~high-affinity~~ modified sugar, ~~or a modified nucleobase, or combination thereof.~~

53. (Previously Presented) The compound of claim 52 having at least one 2'-O-methoxyethyl sugar moiety.

54. (Previously Presented) The compound of claim 52 having at least one phosphorothioate internucleoside linkage.

55. (Previously Presented) The compound of claim 52 having at least one 5-methylcytosine.

56. (Previously Presented) The compound of claim 52 that is a pharmaceutically acceptable salt.

57. (Previously Presented) The compound of claim 50 that is a pharmaceutically acceptable salt.

58. (New) The compound of claim 1, wherein said compound is at least 95% complimentary to SEQ ID NO: 4 as measured over the entire length of said compound.

59. (New) The compound of claim 1, wherein said compound is 100% complimentary to SEQ ID NO: 4 as measured over the entire length of said compound.

60. (New) The compound of claim 46, wherein said compound is 20 nucleotides in length.

61. (New) The compound of claim 50, wherein said compound is at least 95% complementary with SEQ ID NO: 4 as measured over the entire length of said compound.

62. (New) The compound of claim 50, wherein said compound comprises the nucleic acid sequence of SEQ ID NO: 19.

63. (New) A compound targeted to a nucleic acid molecule encoding growth hormone receptor, said compound comprising:

an at least 8 consecutive nucleobase portion of SEQ ID NO: 19;

wherein said compound is from 8 to 80 nucleobases in length; and

wherein said compound is at least 90% complementary with SEQ ID NO: 4 as measured over the entirety of said compound.

Appl. No. : 10/789,526
Filed : February 26, 2004

64. (New) The compound of claim 60, wherein said compound is at least 95% complementary with SEQ ID NO: 4 as measured over the entire length of said compound.

65. (New) The compound of claim 60, wherein said compound is 100% complementary with SEQ ID NO: 4 as measured over the entire length of said compound.

66. (New) The compound of claim 60, wherein said compound is an oligonucleotide.

67. (New) The compound of claim 66, comprising at least one 2'-O-(2-methoxyethyl) nucleotide, at least one phosphorothioate internucleoside linkage, and at least one 5-methylcytosine.

68. (New) The compound of claim 67, further comprising:

a region of deoxynucleotides flanked on both the 5' and the 3' ends of said region with at least one 2'-O-(2-methoxyethyl) nucleotide;

wherein each internucleoside linkages of said compound is a phosphorothioate internucleoside linkage;

and wherein each cytosine of said compound is a 5-methylcytosine.